amneal

We make healthy possible.

Q2 2024 Earnings Call

August 9, 2024

AMRX

Nasdaq Listed

Cautionary Statement on Forward Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as "plans," "expects," "will," "anticipates," "estimates," and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the impact of a prolonged business interruption within our supply chain; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our dependence on third-party agreements for a portion of our product offerings; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties, including recent events affecting the financial services industry; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, and adjusted diluted EPS, which are intended as supplemental measures of the Company's performance that are not required by or presented in accordance with GAAP. Adjusted diluted EPS reflects diluted earnings per share based on adjusted net income, which is net loss adjusted to (A) exclude (i) non-cash interest, (ii) GAAP provision for income taxes, (iii) amortization, (iv) stock-based compensation, (v) acquisition, site closure expenses, and idle facility expenses, (vi) restructuring and other charges, (vii) charges related to certain legal matters, including interest, net, (viii) asset impairment charges, (ix) change in fair value of contingent consideration, (x) increase in tax receivable agreement liability, (xi) system implementation expense, (xii) other and (xiii) net income attributable to non-controlling interests not associated with Class B common stock, and (B) include non-GAAP provision for income taxes. Non-GAAP adjusted diluted EPS for the three months ended June 30, 2024 was calculated assuming the weighted average diluted shares outstanding of Class A common stock. Non-GAAP adjusted diluted EPS for the three months ended March 31, 2023 was calculated assuming (i) the weighted average diluted shares outstanding of Class A common stock and (ii) as if all shares of Class B common stock were converted to shares of Class A common stock as of January 1, 2023. Management uses these non-GAAP measures internally to evaluate and manage the Company's operations and to better understand its business because they facilitate a comparative assessment of the Company's operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company's operations and underlying operational performance. The compensation committee of the Company's board of directors also uses certain of these measures to evaluate management's performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company's financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company's financial performance, results of operations and trends while viewing the information through the eyes of management. These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company's financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company's GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP.

Q2 2024 Earnings Call

Agenda	
1	**Strategy & Business Update** Chirag and Chintu Patel, Co-founders and Co-CEOs
2	**Financial Results** Tasos Konidaris, EVP & CFO
3	**Q&A**

Chirag Patel,
Co-CEO and President

Chintu Patel,
Co-CEO



Tasos Konidaris,
EVP & CFO

Andy Boyer,
EVP - Generics

Joe Renda,
SVP - Specialty

Jason Daly, SVP
& Chief Legal Officer

Q2 2024 key highlights

Record Q2 Revenue and Adjusted EBITDA	• **Record quarterly financial performance with net revenue of $702M up 17%, and adjusted EBITDA of $162M, up 11%** • Broad-based growth across all three business segments
Raised Full Year 2024 Guidance	• **Increased 2024 guidance to $2.7B to $2.8B revenues and $610M to $630M adjusted EBITDA,** reflects double-digit top and bottom-line growth versus 2023
Approval of CREXONT® for Parkinson's	• **CREXONT® (IPX203) received U.S. FDA approval** • Launch planned in September with expected peak U.S. sales of $300-500M
Continued Deleveraging	• **Reduced net leverage to 4.4x in Q2**, down from 4.8x at 2023 year-end; higher profitability and cash generation allow for gross debt reduction over time

Executing on Amneal's four pillars of value creation

Key Pillar		Metric	2019	2023	LTM[3] Q2 2024	Growth projection[4]
#1	Increased diversification	OSD[1] Gx % of total revenue	53%	25%	25%	<20% of revenue by 2027
#2	Strong financial performance	Revenues	$1.6B	$2.4B	$2.6B	High single-digit growth
		Adjusted EBITDA	$339M	$558M	$611M	Meaningful acceleration
#3	Cash generation	Operating Cash Flow[2]	$2M	$346M	$252M	Sustained higher levels of cash flow generation
#4	Deleveraging	Net Leverage	7.4x at 12/31/19	4.8x at 12/31/23	4.4x at 6/30/24	< 4x in 2025, < 3x thereafter

(1) OSD = Oral Solid. AvKARE sales of Amneal label products, royalty income and international revenues are included within Generics Non-OSD consistent with how the Company manages its portfolio. Projection excludes select high-value OSD products that are highly complex with limited competition.
(2) 2023 benefited from strong AR collections (105% of net sales) which added ~$125M to 2023 operating cash flow.
(3) LTM = Last Twelve Months
(4) Growth projection reflects the potential outcomes of delivering our long-term strategy and is based on the current macro environment and expected product pipeline launches, among other assumptions.

Global diversified pharmaceutical company with a clear strategy for sustainable growth

Business area	Net Revenue LTM Q2 2024	Strategy for growth	Growth projection[1]	
Retail	**$1.573B**	**Grow #4 U.S. Generics portfolio** of **~240 products** with **new launches** and **shift to complex dosage forms**	**Low-single digit growth**	**High-single digit growth**
Injectables		Expand portfolio of **40+ institutional products** through **new launches** and leverage **new capacity** to be **Top 5 in U.S. and a global player**	**$300M+** revenue by 2025	
Biosimilars		Drive **initial portfolio** and **add more biosimilars** to the pipeline to be **Top 5 in U.S. and a global player**	**$200M+** peak U.S. sales by 2025 from 1st 3 biosimilars[2]	
International		**Market expansion** in India, Europe, China and rest of the world – **either direct or through licensing**	Add **$50-100M** revenue by 2027	
Specialty	**$411M**	Grow **branded portfolio** with focus on **Neurology** and **Endocrinology**	**$500M+** revenue by 2027 reflecting **high-single digit growth**	
AvKARE	**$614M**	Grow across **distribution, government** and **institutional channels**	**$675M+** by 2025 reflecting **double-digit growth**	

(1) Growth projection reflects the potential outcomes of delivering our long-term strategy and is based on the current macro environment and expected product pipeline launches, among other assumptions.
(2) Represents the total peak U.S. sales for our first three oncology biosimilars (filgrastim, pegfilgrastim and bevacizumab).

Parkinson's Disease is a progressive neurological disorder

Parkinson's Disease (PD) overview

- **Degenerative and incurable neurological disease** due to progressive loss of dopamine-producing cells needed to regulate movement
- Symptoms include resting tremor, stiffness/rigidity, slow movement and impaired balance and coordination

~1M	+90k	>10M
Total U.S. PD patient population[1]	New U.S. PD diagnosis each year[1]	Total global PD patient population[1]

A new PD patient is diagnosed every 6 minutes

Therapeutic window narrows over time

- **Carbidopa/levodopa** (CD/LD) therapy replaces dopamine to manage symptoms of PD and has been the gold standard treatment for 50+ years – **used by >90% of U.S. PD patients**[2]



- Therapeutic window narrows as disease progresses – making it difficult to achieve consistent symptom relief
- As disease progresses, PD patients develop motor fluctuations and **require more frequent daily IR doses (up to 10),** causing a burden for patients and reducing medication adherence[3]

Over 40% of patients within 2.5 years of diagnosis experience wearing-off symptoms[4]

(1) Source: Parkinson's Foundation. https://www.parkinson.org/understanding-parkinsons/statistics
(2) Per IQVIA, based on 12-month moving average as of May 2024.
(3) Espay AJ et al. Neurol Clin Pract. 2017;7:86-93.
(4) Stocchi F et al. Parkinsonism Relat Disord. 2014;20(2):204-211

Current PD treatment landscape in the U.S.

Current strategies for treating motor fluctuations in PD patients [1]

Increase:
Dose/frequency of immediate-release CD/LD

Switch:
To a longer-acting CD/LD

Add-on (options):
COMT inhibitor; Dopamine agonist; MAO-B inhibitor; Rescue medication



Need for longer-lasting relief from symptoms for Parkinson's patients – enter CREXONT

(1) Gupta HV et al. Drugs Aging. 2019;36(9):807-821.

Amneal Parkinson's Disease product offering

Introducing CREXONT® – a new treatment for Parkinson's

CREXONT®
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
35mg/140mg · 52.5mg/210mg
70mg/280mg · 87.5mg/350mg

Novel, long-lasting CD/LD formulation

- Contains IR granules with carbidopa and levodopa for rapid onset of action, and ER pellets with levodopa for long-lasting efficacy(1)



(1) IR = Immediate-release; ER = Extended-release
(2) Hauser RA, Espay AJ, Ellenbogen AL, et al. IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease: the RISE-PD randomized clinical trial. JAMA Neurol. 2023;80(10):1062-1069.

CREXONT® provides more “Good On” time for PD patients

- **+0.5 hours more “Good On” time per day while taking CREXONT 3 times per day as compared to IR CD/LD 5 times per day**, per Phase 3 study (P=0.0194)[1]
- **+1.6 hours more “Good On” time per dose with CREXONT,** per Phase 3 post-hoc analysis (P<0.001)[2]





- **A single dose of CREXONT sustained LD plasma concentrations greater than 50% of Cmax for 4.8 hours** compared to 1.9 hours for IR (p<0.0001) and 3.9 hours for Rytary (p=0.01)[3]
- **+0.9 hours more daily “Good On” time than Rytary**, per Phase 2 study (P=0.026)[4]

Note: CD/LD=carbidopa/levodopa; IR=immediate-release; LS=least squares.

(1) Results from the RISE-PD study, a 20-week, phase 3, randomized, double-blind, double-dummy, active-control, parallel-group trial that examined the safety and efficacy of IPX203 in Parkinson’s Disease patients experiencing motor fluctuations. Hauser RA, et al. JAMA Neurol. 2023;80(10):1062-1069.

(2) Results for Phase 3 post-hoc analysis of “Good On” time per dose was defined as daily “Good On” time (hours) divided by the daily dosing frequency in the subject's stable dosing regimen, as determined at the end of the dose adjustment period for subjects randomized to IR CD/LD and at the end of the CREXONT conversion period for subjects randomized to CREXONT. Hauser RA, et al. JAMA Neurol. 2023;80(10):1062-1069.

(3) Results from a single-dose, open-label, phase 2a study in PD patients with motor fluctuations indicated that LD plasma concentrations were sustained >50% maximum concentration (Cmax) for 4.8 and 3.9 hours for IPX203 and Rytary, respectively. Amneal data on file package.

(4) Results from a single-dose, open-label, phase 2a study in PD patients with motor fluctuations, the mean “Off ” time was 4.5 hours following IPX203 treatment and 5.4 hours following Rytary, demonstrating a 0.9-hour advantage for IPX203 over Rytary. The reduction in “Off ” time with IPX203 was accompanied by a corresponding increase in “Good On” time, demonstrating 0.9 hours more “Good On” time vs Rytary. Modi NB, et al. Clin Neuropharmacol. 2019;42(1):4-8. 4.

CREXONT® commercial strategy to reach more patients

Current U.S. PD Market of patients on CD/LD[1]



Rytary is ~$200M product at ~6% share

Clear opportunity to drive broader adoption of CREXONT for the full CD/LD patient population

- **September launch is planned** leveraging strong commercial and medical foundation and relationships built over the last 10 years based on Rytary experience
- **Compelling value proposition** for patients, providers and payers
- **Primary focus is on current IR CD/LD patients** and new PD patients
- **Prescriber focus broadened to general neurology:** ~12,000 neurologist in the U.S.; ~700 are movement disorder specialists which was historical focus with Rytary
- **Rytary is #1 payor covered branded PD product** at ~70%; we are targeting similar coverage with CREXONT

Expect $300-500M U.S. peak sales from CREXONT

(1) Per IQVIA, based on 12-month moving average as of May 2024. IR = Immediate Release; CR = Continuous Release; ER = Extended Release

Keys to successful CREXONT® commercialization

Novel formulation that advances standard of care	10 years of experience with PD providers, payers and patients	Deep clinician and advocacy engagement informs our work	Strong commercial, managed care and MSL organization is ready	Best-in-class HCP & patient solutions to improve access
				
• More “Good On" time per day and per dose • Simple dose conversion from IR	• Rytary® is the leading branded product in the CD/LD market since 2015 launch	• Commercial strategy informed by patient, provider, care partner, and payer studies	• 100+ person team of sales, market access and medical affairs • Targeting coverage comparable to Rytary	• Patient support services including enrollment, patient financial assistance and reimbursement

Recent and upcoming growth catalysts across portfolio

	Retail	Injectables	Biosimilars	Specialty	International
Achieved in 2024	✓ **Launched:** **Naloxone nasal spray**, **Fluorometholone acetate**, Carvedilol ER, Darunavir, **Ciprofloxacin and Dexamethasone Otic Suspension** ✓ **Approved:** Lacosamide oral solution, Fosfomycin Tromethamine granules for oral solution, Ofloxacin ophthalmic solution, Pitavastain, Timolol Maleate, Azelastine Hydrochloride Nasal Spray, Estradiol Gel, Bromfenac opthalmic solution	✓ **Launched:** Ropivacaine (IV bag), Atropine Sulfate (PFS[1]), Docetaxel, **Methylprednisolone acetate** (MDV[2]), Calcium Gluconate and 2 RTU[3] 505(b)(2) products: **PEMRYDI®** and **FOCINVEZ®** ✓ **Approved:** Calcium Chloride, 3rd RTU 505(b)(2): **Potassium phosphate** (IV bag)	✓ **Driving uptake of:** **ALYMSYS®** (bevacizumab), **RELUEKO®** (filgrastim), & **FYLNETRA®** (peg-filgrastim)	✓ **Launched:** **ONGENTYS®** (Parkinson's Disease adjunctive therapy) ✓ **Approved:** **CREXONT®** - IPX203 (Parkinson's Disease) – September launch	✓ **Launched:** India: Ophthalmics, Oncology and Diagnostics ✓ **Product registrations:** Registering products with our global distribution partners
Expected 2024/2025 launches and key activities	**2024:** **Mesalamine**, **Gx ProAir®**, Bupropion, Clindamycin phosphate topical, Everolimus, Isotretinoin, Loteprednol etabonate ophthalmic, Scopolamine, Tiopronin EC, Hydrocortisone solution **2025:** **Gx Restasis®**, **Gx Pred-Forte®**, **Eltrombopag**, **Gx Venofer®**, **Gx Xyrem®**, Memantine/Donepezil ER Additional opportunities not disclosed	**2024:** Exenatide pen injector, **Propofol emulsion**, Edaravone, Sodium phosphate, Labetalol, Nicardipine, Phytonadione **2025:** **Gx Risperdal Consta®**, **Epinephrine** (MDV[3] & SDV[4] vials and PFS[1]), Hydrocortisone sodium succinate (vial), Sodium bicarbonate (vial) and **2-3 505(b)(2) RTU products** Additional opportunities not disclosed	**Q4'24 filing:** **2 denosumab biosimilars** (for Prolia® & XGEVA®) **Q1'25 filing:** **2 peg-filgrastim biosimilars** (On-Body injector & Prefilled autoinjector for Neulasta®) **Q4'25 filing:** **omalizumab biosimilar** (for Xolair®) Look to in-license 1-2 or more biosimilars per year	**Q2 2025:** **DHE autoinjector** (migraine and cluster headache)	• **Registering** additional products in new geographies

Potential high-value opportunities

(1) PFS = Prefilled Syringe; (2) MDV = Multiple-dose vial; (3) RTU = Ready-to-use; (4) SDV = Single-dose vial

Key near-term growth drivers



	Retail & Injectables New Launches	Naloxone HCl Nasal Spray	ALYMSYS®	CREXONT® (formerly IPX203)	DHE Autoinjector
Product type	Generics portfolio	Complex generics	Biosimilar	Specialty	Specialty
Therapeutic area	All areas	Anti-overdose	Oncology	Parkinson's Disease	Migraine and Cluster Headache
Expected Launch	30+ each year	✓ Q2 2024	✓ Q4 2022	✓ Q3 2024	Q2 2025
Importance	Expands and diversifies portfolio with complex products and drives continued growth	Increases access to OTC(2) and affordable treatment as opioid crisis remains a U.S. Public Health Emergency	Key oncology therapy with growing market share	+1.6 more hours of "Good On" time per IR dose	Prefilled and ready-to-use autoinjector for an easy-to-use treatment option
Market opportunity	Expect $100M+ in new product revenue in 2024(1)	Expect $30M+ sales in 2024; up to 5M unit capacity in 2025	Expect $100M+ sales by 2025	Estimated ~$300M - $500M U.S. sales opportunity	Estimated ~$50M - $100M U.S. sales opportunity

(1) Reflects expected 2024 new launches and the impact of 2023 new launches annualizing. Note: This does not include naloxone, which is listed separately above.
(2) OTC = Over-the-Counter

Our portfolio continues to diversify – making growth sustainable

Purposeful mix shift towards a more complex portfolio

Generics net revenues mix ($'s)



Pipeline mix (# of products)

Diversified revenues driving sustainable growth

Total company net revenues mix ($'s)



Note: Total may not add due to rounding. LTM = Last Twelve Months

(1) AvKARE sales of Amneal label products, royalty income and international revenues are included within Generics Non-OSD consistent with how the Company manages its portfolio.

Deep pipeline as our wheel of innovation keeps turning



Developing pipeline across increasingly complex dosage forms with **94% non-oral solids**

Pending ANDA's across dosage forms with **63% non-oral solids**



Refreshing pipeline by filing **25-30 ANDAs** and launching **30+ new products each year**

Note: Total Addressable market (TAM) are approximate IQVIA (brand + active generics) MAT May 2024 sales ($ in millions).
For ANDA charts, Single Source: One active player other than RLD / RS. FTM: First to market (No IP/ No Generic). PIV: Paragraph IV certification. LOA: Launch upon approval. eFTF: exclusive first to file. High Value: large size opportunity for Amneal.

Expanding injectables portfolio to drive substantial growth

Significant U.S. injectables market needs

- Notable supply chain disruptions across various players and chronic drug shortages, including oncology injectables
- American Society of Health System Pharmacists (ASHP) lists 300 active U.S. drug shortages, with about half injectables[(1)]

Differentiated portfolio

- **Expand portfolio of 40+ injectables** by launching **10+ new products each year**
- **Focused on complex areas**, such as drug/device, peptides, long-acting injectables and LVP bags
- **Deep commercial capabilities** across hospital and oncology market segments to drive differentiated value proposition

Expanded capacity

- **Expanded capacity from ~20M to ~60M units** across 4 manufacturing sites with overlapping redundancy
- Manufacturing capabilities across dosage forms with vials, bottles, pre-mixed bags, pre-filled syringes and cytotoxic oncology

Launched 1st 505(b)(2) RTU[(2)] injectables

- **New vector for Injectables growth with compelling value proposition for clinicians**
- Launch of **PEMRYDI RTU®**, 1st RTU version of pemetrexed (for treating lung cancer)
- Launch of **FOCINVEZ®**, 1st RTU version of fosaprepitant (for prevention of nausea due to chemotherapy)
- Approval of **Potassium Phosphates IV bags**, 1st RTU version of commonly used and compounded injectable

Expect $300M+ injectables revenues by 2025

(1) Per ASHP active drug shortage report as of June 2024.
(2) RTU = Ready-to-use

Rapidly growing biosimilars with key oncology medicines

Strong commercial uptake

ALYMSYS® bevacizumab-maly (Avastin®)

FYLNETRA® pegfilgrastim-pbbk (Neulasta®)



RELEUKO® filgrastim-ayow (Neupogen®)

Expect $200M+ in 2025 revenues from first 3 biosimilars

Expected biosimilar pipeline launches[2]

BLA[1] filing	Biosimilar (Biologic)	Therapeutic areas
Q4 2024	denosumab (Prolia®)	osteoporosis
Q4 2024	denosumab (XGEVA®)	bone cancer
Q1 2025	peg-filgrastim on-body injector (Neulasta®)	neutropenia
Q1 2025	peg-filgrastim prefilled autoinjector (Neulasta®)	neutropenia
Q4 2025	omalizumab (Xolair®)	asthma and allergies

Rapidly growing market

- **~$192B branded products losing exclusivity 2024-2028**[3], including key biologic medicines
- **Growing biosimilar adoption** with categories like Bevacizumab at 80%+ biosimilar adoption
- **Focused on medical benefit products** at physician site of care with more stable dynamics
- Look to **in-license 1 to 2 biosimilars per year** or more

Note: All trademarks are the property of their respective owners.
(1) BLA = Biologics License Application.
(2) Pipeline includes investigational products not approved by FDA. Any such expected launch is subject to certain assumptions and factors, many of which are outside our control, such as regulatory approval, and may be subject to change.
(3) Per IQVIA report: The Global Use of Medicines 2024: Outlook to 2028.

Delivering continued double-digit growth in AvKARE



AvKARE strategic focus areas

- **Operates as a contract administrator** (wholesaler and re-packager selling to hospitals and U.S. Government agencies) with 3 sales channels:
  - **Government (VA & DOD)** with long-term contracts
  - **Distribution** focused on public health institutions and retail pharmacies
  - **Unit Dose** through novel re-packaging solutions

Well-positioned for long-term growth driven by new products and new customer channels

Note: Figures above exclude Amneal label generic products sold through AvKARE, which are included in our Generics segment results.

Expanding our Specialty business with new branded products

Specialty highlights

- Therapeutic focus on **Neurology** and **Endocrinology**
- **Approval of CREXONT®**, formerly known as IPX203
- **Added ONGENTYS®**, an adjunctive therapy for Parkinson's Disease
- Look to **add more Specialty assets** through business development

Key brands continue to grow



Expected specialty pipeline launches(1)

Potential Launch	Program	Therapeutic Area
Launched Q1 2024	ONGENTYS®	Parkinson's Disease
September	CREXONT®	Parkinson's Disease
Q2 2025	DHE Autoinjector	Migraine and Cluster Headache
2026-2027	K-114	Hypothyroidism

Expect $500M+ sales by 2027

Note: Totals may not add due to rounding.
(1) Pipeline includes investigational products not approved by FDA. Any such expected launch is subject to certain assumptions and factors, many of which are outside our control, such as regulatory approval, and may be subject to change.

Building the foundation for international expansion

Geography	Direct / Partner	Strategy and status
India	**Direct** Expanding local presence	• Focusing on hospital critical care, diagnostics, ophthalmics, oncology and specialty markets • Utilizing local commercial team
Europe	**Partner** Orion Corporation	• Registering select products
China	**Partner** Fosun Pharmaceuticals	• First 2 products approved • 8 additional products under review
Canada	**Partner** Sterimax	• Focused on injectables
Rest of the World	**Partners** Not disclosed	• Partnerships in ~20 countries (Middle East, Africa, Latin America and Southeast Asia) and registering products underway
CREXONT® Globally	**Partners** Europe – Zambon Canada & Latin America – Knight	• Partnerships established with first international partners for IPX203



Purpose-driven company with ESG tenets instilled throughout

Environment	In June, Amneal released its fourth ESG report for 2023. Notably, we **reduced greenhouse gas emissions by 131 metric tons of carbon dioxide at our Kentucky sites in 2023.**	
Innovative medicines	In July, we announced the **expansion of our biosimilar pipeline** with the addition of omalizumab, referencing **Xolair®,** in partnership with Kashiv Biosciences, LLC.	
Launching Complex Innovations	In April, we launched **OTC Naloxone HCL Nasal Spray**, a medication that is used to **help treat opioid drug overdoses**, including heroin, fentanyl and prescription opioid medications.	
Governance	In the last year, we have introduced a **new ESG taskforce** to advise and guide the business, leadership team and Board **on the ESG regulatory and compliance requirements.**	

Strong financial performance across all business segments

Net Revenue Growth



Net Revenue +10% CAGR from 2019 to 2023

Adjusted EBITDA(2) Growth



Adjusted EBITDA +13% CAGR from 2019 to 2023

Note: Totals may not add due to rounding.

(1) New launches reflects new Generics product launches since 2019, which includes biosimilars of $66M in 2023 and $125M+ expected in 2024.

(2) Adjusted EBITDA is a non-GAAP measure. Please see language under the heading "Non-GAAP Financial Measures" in the most recent earnings presentation for a discussion of Non-GAAP measures. Refer to appendix for reconciliations.

Q2 2024 financial performance

Results[1] $ millions except for EPS	Q2 2024	Q2 2023	Change	Key Drivers / Commentary
Net Revenue	**$702**	$599	**+17.1%**	• Broad-based growth across all business segments
Adjusted Gross Margin	**41.0%**	43.3%	**(230 bps)**	• In-line with expectations; Business mix due to AvKARE high growth
Adjusted R&D Expense	**$36**	$38	**+4.1%**	• Lower mostly due to timing of investments
Adjusted SG&A Expense	**$104**	$92	**(13.8%)**	• Increased commercial investments for new products
Adjusted EBITDA	**$162**	$146	**+11.0%**	• Strong revenue performance and operating expense leverage
Adjusted Diluted EPS	**$0.16**	$0.19	**(15.8%)**	• Adjusted EBITDA growth offset by higher interest expense
Operating Cash Flow	**$40**	($11)	**NM**	• Typical quarterly fluctuations; Includes timing of receivables & collections

(1) Please see the language under the heading "Non-GAAP Financial Measures" in today's press release for a discussion of these Non-GAAP measures and the Appendix to this presentation for a reconciliation thereof to the most directly comparable GAAP measures.

First half 2024 financial performance

Results[1] $ millions except for EPS	1H 2024	1H 2023	Change	Key Drivers / Commentary
Net Revenue	**$1,361**	$1,157	**+17.7%**	• Broad-based double-digit growth across all business segments
Adjusted Gross Margin	**41.4%**	41.4%	**-**	• In-line with prior year
Adjusted R&D Expense	**$76**	$77	**+1.6%**	• In-line with prior year
Adjusted SG&A Expense	**$206**	$183	**(12.5%)**	• Increased commercial investments for new products
Adjusted EBITDA	**$315**	$262	**+19.9%**	• Strong revenue performance and operating expense leverage
Adjusted Diluted EPS	**$0.30**	$0.31	**(3.2%)**	• Adjusted EBITDA growth offset by higher interest expense and share count
Operating Cash Flow	**$35**	$128	**(72.5%)**	• Typical quarterly fluctuations; Includes timing of receivables & collections
Operating Cash Flow, ex-discrete items[2]	**$88**	$214	**(59.0%)**	• Note: Final Opana litigation payment made in January 2024

(1) Please see the language under the heading "Non-GAAP Financial Measures" in today's press release for a discussion of these Non-GAAP measures and the Appendix to this presentation for a reconciliation thereof to the most directly comparable GAAP measures.
(2) OCF ex-discrete items excludes legal settlement payments and associated legal and other professional services fees, primarily related to the settlements of the Opana ER® antitrust litigation.

Performance by segment

Results[1] $ millions		Second Quarter 2024	Second Quarter 2023	First Half 2024	First Half 2023	Q2 Key Drivers / Commentary
Generics	Net Revenue	**$427 +14.4%**	$374	**$819 +14.1%**	$718	• Strong performance of biosimilars and new launches
	Adjusted Gross Margin	**41.6% (170 bps)**	43.3%	**41.7% +120 bps**	40.5%	• Unfavorable mix and higher plant spend
Specialty	Net Revenue	**$104 +7.3%**	$97	**$209 +10.9%**	$189	• Growth of promoted products and addition of ONGENTYS®
	Adjusted Gross Margin	**80.6% +190 bps**	78.7%	**81.4% +140 bps**	80.0%	• Favorable product mix
AvKARE	Net Revenue	**$170 +32.8%**	$128	**$333 +33.0%**	$250	• Continued growth across all 3 sales channels
	Adjusted Gross Margin	**15.0% (140 bps)**	16.4%	**15.6% +60 bps**	15.0%	• Channel mix from higher distribution channel sales

(1) Please see the language under the heading "Non-GAAP Financial Measures" in today's press release for a discussion of these Non-GAAP measures and the Appendix to this presentation for a reconciliation thereof to the most directly comparable GAAP measures.

Raising full year 2024 guidance

	Updated 2024 Guidance[1]	Prior 2024 Guidance[1]	2023 Actual
Net Revenue	**$2.70 – $2.80B**	**$2.55 – $2.65B**	**$2.4B**
Adjusted EBITDA	**$610 – $630M**	**$580 – $620M**	**$558M**
Adjusted Diluted EPS[2]	**$0.57 – $0.63**	**$0.53 – $0.63**	**$0.64**
Operating Cash Flow, ex-discrete items[3]	$280 – $320M	$260 – $300M	$431M
Operating Cash Flow	N/A	N/A	$346M
Capital Expenditures	$60 – $70M	$60 – $70M	$43M

(1) Amneal's full year 2024 estimates are based on management's expectations, including with respect to prescription trends, pricing levels, inventory levels, the costs incurred and benefits realized of restructuring activities and the anticipated timing of future product launches and events. Please see language under the heading "Non-GAAP Financial Measures" in today's press release for a discussion of these Non-GAAP measures and the Appendix to this presentation for a reconciliation thereof to the most directly comparable GAAP measures. Non-GAAP estimates cannot be reconciled without unreasonable effort.

(2) Assumes weighted average diluted shares outstanding of ~320 million in updated 2024 guidance and ~317 million in prior 2024 guidance, compared to 310 million shares outstanding in 2023.

(3) Operating Cash Flow (OCF) guidance for 2024 does not contemplate one-time and non-recurring items such as legal settlements and other discrete items. 2023 OCF ex-discrete items excludes $86M in legal settlement payments and associated legal and other professional services fees, primarily related to the settlements of the Opana ER® antitrust litigation.

Strong cash generation and continued deleveraging

$ millions	2024E	2023	2022
Net Revenue	**$2,700 - $2,800**	$2,394	$2,212
Adjusted EBITDA	**$610 - $630**	$558	$514
% of Net Revenue	*~22.5%*	*23.3%*	*23.2%*
Operating Cash Flow ex-discrete items[1]	**$280 - $320**	$431[2]	$211
% of Adjusted EBITDA	*45% - 50%*	*77%*	*41%*
Operating Cash Flow		$346[2]	$65

$ millions	Jun 30, 2024	Dec. 31, 2023
Gross debt[3]	**$2,726**	$2,767
Total cash[4]	**$44**	$92
Net debt[5]	**$2,682**	$2,675
LTM Adjusted EBITDA[6]	**$611**	$558
Gross leverage	**4.5x**	5.0x
Net leverage	**4.4x**	4.8x

Capital allocation priorities	• **Continued investments in organic growth, reduce leverage and "tuck-in" business development**

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

(1) OCF ex-discrete items in 2024 does not contemplate one-time and non-recurring items such as legal settlements and other discrete items. OCF ex-discrete items excludes $86M in 2023 and $146M in 2022 in legal settlement payments and associated legal and other professional services fees, primarily related to the settlements of the Opana ER® antitrust litigation.

(2) 2023 benefited from strong AR collections (105% of net sales) which added ~$125M to 2023 operating cash flow.

(3) Includes Term Loan B (TLB) maturities due in 2025 and 2028, borrowings under the revolving credit facilities due in 2027, and Rondo sellers note.

(4) Includes cash and cash equivalents.

(5) Net debt = Gross debt less total cash.

(6) Please see the language under the heading "Non-GAAP Financial Measures" in today's presentation for a discussion of these Non-GAAP measures and the Appendix to this presentation for a reconciliation thereof to the most directly comparable GAAP measures.

We make healthy possible.

Appendix: Non-GAAP Reconciliations



Reconciliation of net income (loss) to EBITDA and Adjusted EBITDA

($) in millions	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Net income (loss)	**$ 16.8**	**$ 29.7**	**$ (64.9)**	**$ 19.6**
Adjusted to add:				
Interest expense, net	65.7	50.9	131.4	100.2
Provision for income taxes	3.6	—	9.8	0.6
Depreciation and amortization	55.6	57.1	111.1	115.3
EBITDA (Non-GAAP)	**$ 141.7**	**$ 137.7**	**$ 187.4**	**$ 235.7**
Adjusted to add (deduct):				
Stock-based compensation expense	6.7	6.6	13.2	14.2
Acquisition, site closure, and idle facility expenses	0.6	1.6	1.0	4.3
Restructuring and other charges	0.1	0.1	1.6	0.5
Charges related to legal matters, net	0.7	2.0	95.1	6.1
Asset impairment charges	—	1.3	1.0	2.1
Foreign exchange loss (gain)	0.3	(0.4)	1.5	(2.3)
Change in fair value of contingent consideration	—	(6.4)	0.1	(3.9)
Increase in tax receivable agreement liability	13.4	0.4	15.4	1.2
System implementation expense	0.9	1.7	1.8	2.4
Other	(2.2)	1.6	(3.5)	2.1
Adjusted EBITDA (Non-GAAP)	**$ 162.2**	**$ 146.1**	**$ 314.6**	**$ 262.3**

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Reconciliation of net (loss) income to EBITDA and Adjusted EBITDA

($) in millions	Year Ended December 31, 2023	2022	2021	2020	2019
Net (loss) income	**$ (48.7)**	**$ (254.8)**	**$ 20.1**	**$ 68.6**	**$ (603.6)**
Adjusted to add:					
Interest expense, net	210.6	158.4	136.3	146.0	168.2
Provision for (benefit from) income taxes	8.5	6.7	11.2	(104.4)	383.3
Depreciation and amortization	229.4	240.2	233.4	235.4	207.3
EBITDA (Non-GAAP)	**$ 399.8**	**$ 150.4**	**$ 401.0**	**$ 345.6**	**$ 155.2**
Adjusted to add (deduct):					
Stock-based compensation expense	26.8	31.8	28.4	20.8	21.7
Acquisition, site closure, and idle facility expenses	7.0	15.7	20.0	23.4	73.5
Restructuring and other charges	1.7	1.4	0.8	2.4	34.3
Loss on refinancing	40.8	0.3	—	—	—
Inventory related charges	—	—	0.3	6.6	25.7
Charges related to legal matters, net	11.8	269.9	25.0	5.6	12.6
Asset impairment charges	70.1	26.9	24.1	43.6	175.2
Foreign exchange (gain) loss	(1.7)	12.4	0.4	(16.4)	5.0
Change in fair value of contingent consideration	(14.5)	0.7	0.2	—	—
(Insurance recoveries) charges for property losses and associated expenses, net	—	(1.9)	5.4	—	—
Regulatory approval milestone	—	5.0	—	—	—
Amortization of upfront payment	—	—	—	—	36.4
Gain on sale of business	—	—	—	(0.1)	(7.3)
Increase (decrease) in tax receivable agreement	3.1	0.6	—	—	(192.9)
System implementation expense	5.4	2.8	0.8	—	—
Reorganization expense	5.9	0.4	—	—	—
Other	2.0	(2.4)	5.9	1.9	(0.4)
Adjusted EBITDA (Non-GAAP)	**$ 558.2**	**$ 514.1**	**$ 512.3**	**$ 433.4**	**$ 339.0**

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Reconciliation of net income (loss) to adjusted results

($) in millions	Three Months Ended June 30, 2024	Three Months Ended June 30, 2023	Six Months Ended June 30, 2024	Six Months Ended June 30, 2023	Year Ended December 31, 2023
Net income (loss)	**$ 16.8**	**$ 29.7**	**$ (64.9)**	**$ 19.6**	**$ (48.7)**
Adjusted to add (deduct):					
Non-cash interest	0.5	2.1	0.6	4.0	7.0
GAAP provision for income taxes	3.6	—	9.8	0.6	8.5
Amortization	38.8	39.3	77.5	78.9	157.2
Stock-based compensation expense	6.7	6.6	13.2	14.2	26.8
Acquisition, site closure expenses, and idle facility	0.6	1.6	1.0	4.3	7.0
Restructuring and other charges	0.1	0.1	1.6	0.5	1.7
Loss on refinancing	—	—	—	—	40.8
Charges related to legal matters, net	0.7	2.7	95.2	7.6	14.8
Asset impairment charges	—	1.3	1.0	2.1	70.0
Change in fair value of contingent consideration	—	(6.4)	0.1	(3.9)	(14.5)
Increase in tax receivable agreement liability	13.4	0.4	15.4	1.2	3.1
System implementation expense	0.9	1.7	1.8	2.4	5.4
Reorginization expenses	—	—	—	—	5.9
Other	(2.2)	1.6	(3.5)	2.3	2.5
Provision for income taxes	(17.8)	(16.5)	(32.1)	(27.3)	(60.0)
Net income attributable to non-controlling interests not associated with our Class B common stock	(10.8)	(7.3)	(20.8)	(12.7)	(29.9)
Adjusted net income (Non-GAAP)	**$ 51.4**	**$ 56.9**	**$ 95.9**	**$ 93.7**	**$ 197.6**
Diluted EPS (GAAP)	**$ 0.02**	**$ 0.08**	**$ (0.28)**	**$ 0.03**	**$ (0.48)**
Adjusted diluted earnings per share (Non-GAAP)	**$ 0.16**	**$ 0.19**	**$ 0.30**	**$ 0.31**	**$ 0.64**

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Reconciliation of cost of goods sold

($) in millions	Three months ended June 30, 2024	Three months ended June 30, 2023	Six Months Ended June 30, 2024	Six Months Ended June 30, 2023
Net Revenue	$ 701.8	$ 599.0	$ 1,361.0	$ 1,156.6
Cost of goods sold	451.8	379.0	873.0	758.4
Gross profit	**$ 249.9**	**$ 220.0**	**$ 488.0**	**$ 398.2**
Gross margin %	**35.6 %**	**36.7 %**	**35.9 %**	**34.4 %**
Less: adjustments to Costs of goods sold				
Amortization	36.5	36.6	72.9	73.5
Acquisition, site closure, and idle facility expenses	—	1.0	—	3.1
Asset impairment charges	—	1.3	1.0	2.1
Stock-based compensation expense	0.9	0.3	1.8	2.0
Other	—	—	—	0.2
Adjusted Cost of goods sold (Non-GAAP)	414.4	339.8	797.3	677.5
Adjusted Gross Profit (Non-GAAP)	**$ 287.4**	**$ 259.2**	**$ 563.7**	**$ 479.1**
Adjusted Gross Margin % (Non-GAAP)	**41.0 %**	**43.3 %**	**41.4 %**	**41.4 %**

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Reconciliation of segment gross profit to adjusted results

Generics	Three Months Ended June 30, 2024			Three Months Ended June 30, 2023		
($) in millions	As Reported	Adjustments	Non-GAAP	As Reported	Adjustments	Non-GAAP
Net revenue	$ 427.3	$ —	$ 427.3	$ 373.7	$ —	$ 373.7
Cost of goods sold	260.9	(11.4)	249.5	225.2	(13.4)	211.8
Gross profit	**166.4**	**11.4**	**177.9**	**148.5**	**13.4**	**161.9**
Gross margin %	**38.9 %**		**41.6 %**	**39.7 %**		**43.3 %**

Specialty	Three Months Ended June 30, 2024			Three Months Ended June 30, 2023		
($) in millions	As Reported	Adjustments	Non-GAAP	As Reported	Adjustments	Non-GAAP
Net revenue	$ 104.0	$ —	$ 104.0	$ 97.0	$ —	$ 97.0
Cost of goods sold	46.1	(26.0)	20.2	46.5	(25.8)	20.7
Gross profit	**57.9**	**26.0**	**83.9**	**50.5**	**25.8**	**76.3**
Gross margin %	**55.7 %**		**80.6 %**	**52.0 %**		**78.7 %**

AvKARE	Three Months Ended June 30, 2024			Three Months Ended June 30, 2023		
($) in millions	As Reported	Adjustments	Non-GAAP	As Reported	Adjustments	Non-GAAP
Net revenue	$ 170.4	$ —	$ 170.4	$ 128.4	$ —	$ 128.4
Cost of goods sold	144.8	—	144.8	107.3	—	107.3
Gross profit	**25.6**	**—**	**25.6**	**21.0**	**—**	**21.1**
Gross margin %	**15.0 %**		**15.0 %**	**16.4 %**		**16.4 %**

Generics	Six Months Ended June 30, 2024			Six Months Ended June 30, 2023		
($) in millions	As Reported	Adjustments	Non-GAAP	As Reported	Adjustments	Non-GAAP
Net revenue	$ 818.6	$ —	$ 818.6	$ 717.5	$ —	$ 717.5
Cost of goods sold	500.8	(23.7)	477.1	455.7	(28.8)	426.9
Gross profit	**317.8**	**23.7**	**341.5**	**261.8**	**28.8**	**290.6**
Gross margin %	**38.8 %**		**41.7 %**	**36.5 %**		**40.5 %**

Specialty	Six Months Ended June 30, 2024			Six Months Ended June 30, 2023		
($) in millions	As Reported	Adjustments	Non-GAAP	As Reported	Adjustments	Non-GAAP
Net revenue	$ 209.3	$ —	$ 209.3	$ 188.7	$ —	$ 188.7
Cost of goods sold	90.9	(52.0)	39.0	89.7	(52.0)	37.7
Gross profit	**118.3**	**52.0**	**170.3**	**99.0**	**52.0**	**151.0**
Gross margin %	**56.5 %**		**81.4 %**	**52.5 %**		**80.0 %**

AvKARE	Six Months Ended June 30, 2024			Six Months Ended June 30, 2023		
($) in millions	As Reported	Adjustments	Non-GAAP	As Reported	Adjustments	Non-GAAP
Net revenue	$ 333.1	$ —	$ 333.1	$ 250.4	$ —	$ 250.4
Cost of goods sold	281.2	—	281.2	212.9	—	212.9
Gross profit	**51.9**	**—**	**51.9**	**37.5**	**—**	**37.5**
Gross margin %	**15.6 %**		**15.6 %**	**15.0 %**		**15.0 %**

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Additional Reconciliations

Reconciliation of selling, general & administrative to adjusted selling, general & administrative expense:				
	Three Months Ended		Six Months Ended	
($) in millions	June 30, 2024	June 30, 2023	June 30, 2024	June 30, 2023
Selling, general and administrative expense	**$ 116.5**	**$ 105.6**	**$ 229.1**	**$ 207.7**
Adjusted to deduct (add):				
Amortization	3.5	4.2	7.1	8.4
Stock-based compensation expense	5.0	5.5	9.7	10.0
Acquisition, site closure, and idle facility expenses	0.6	0.6	1.0	1.2
Other	3.0	3.5	5.6	5.3
Adjusted selling, general and administrative expense (Non-GAAP)	**$ 104.4**	**$ 91.8**	**$ 205.7**	**$ 182.8**

Reconciliation of research and development to adjusted research and development:				
	Three Months Ended		Six Months Ended	
($) in millions	June 30, 2024	June 30, 2023	June 30, 2024	June 30, 2023
Research and development expense	**$ 36.1**	**$ 37.8**	**$ 75.4**	**$ 76.5**
Intellectual property legal development expenses	**1.0**	**0.8**	**2.0**	**2.5**
Adjusted to deduct:				
Stock-based compensation expense	0.8	0.8	1.8	2.1
Adjusted research and development expense (Non-GAAP)	**$ 36.3**	**$ 37.8**	**$ 75.6**	**$ 76.9**

	Last Twelve Months	Twelve Months Ended	Six Months Ended	
($) in millions	Ended June 30, 2024	December 31, 2023	June 30, 2024	June 30, 2023
Cash provided by operating activities	**$ 252.4**	**$ 345.6**	**$ 35.2**	**$ 128.4**
2022 legal settlements	52.4	85.5	52.4	85.5
Operating Cash Flow, ex-discrete items	**$ 304.8**	**$ 431.1**	**$ 87.6**	**$ 213.9**

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Calculation of Last Twelve Months Gross and Net Leverage

($) in millions	EBITDA	Adjusted EBITDA
Last twelve months (year ended) December 31, 2023 [1]	$ 400	$ 558
Less: Six months ended June 30, 2023 [2]	(236)	(262)
Add: Six months ended June 30, 2024 [3]	187	315
Last twelve months ended June 30, 2024	**$ 352**	**$ 611**

($) in millions	June 30, 2024	December 31, 2023
Term loan due May 2025 [4]	$ 192	$ 192
Term loan due May 2028 [4]	2,322	2,352
Revolving credit facility [4]	179	179
Rondo 5.00% sellers note [4]	33	44
Gross debt	**$ 2,726**	**$ 2,767**
Less: Cash and cash equivalents	(44)	(92)
Net debt	**$ 2,682**	**$ 2,675**

	Last Twelve Months Ended June 30, 2024	Last Twelve Months Ended December 31, 2023
Gross leverage [5]	4.5x	5.0x
Net leverage [6]	4.4x	4.8x

Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

(1) Refer to the Company's 8-K filed with the SEC on March 1, 2024 for a complete reconciliation of our GAAP to non-GAAP results.

(2) Refer to the Company's 8-K filed with the SEC on August 4, 2023 for a complete reconciliation of our GAAP to non-GAAP results.

(3) Refer to EBITDA and Adjusted EBITDA in the GAAP to non-GAAP reconciliation included herein.

(4) Represents contractual principal due.

(5) Calculated by dividing gross debt by adjusted EBITDA for the last twelve months ending June 30, 2024 and December 31, 2023, respectively.

(6) Calculated by dividing net debt by adjusted EBITDA for the last twelve months ending June 30, 2024 and December 31, 2023, respectively.